261 related articles for article (PubMed ID: 28613254)
1. CRISPR/Cas9-Mediated Correction of the FANCD1 Gene in Primary Patient Cells.
Skvarova Kramarzova K; Osborn MJ; Webber BR; DeFeo AP; McElroy AN; Kim CJ; Tolar J
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28613254
[TBL] [Abstract][Full Text] [Related]
2. Effective CRISPR/Cas9-mediated correction of a Fanconi anemia defect by error-prone end joining or templated repair.
van de Vrugt HJ; Harmsen T; Riepsaame J; Alexantya G; van Mil SE; de Vries Y; Bin Ali R; Huijbers IJ; Dorsman JC; Wolthuis RMF; Te Riele H
Sci Rep; 2019 Jan; 9(1):768. PubMed ID: 30683899
[TBL] [Abstract][Full Text] [Related]
3. NHEJ-Mediated Repair of CRISPR-Cas9-Induced DNA Breaks Efficiently Corrects Mutations in HSPCs from Patients with Fanconi Anemia.
Román-Rodríguez FJ; Ugalde L; Álvarez L; Díez B; Ramírez MJ; Risueño C; Cortón M; Bogliolo M; Bernal S; March F; Ayuso C; Hanenberg H; Sevilla J; Rodríguez-Perales S; Torres-Ruiz R; Surrallés J; Bueren JA; Río P
Cell Stem Cell; 2019 Nov; 25(5):607-621.e7. PubMed ID: 31543367
[TBL] [Abstract][Full Text] [Related]
4. CRISPR-Cas9 genome editing in human cells occurs via the Fanconi anemia pathway.
Richardson CD; Kazane KR; Feng SJ; Zelin E; Bray NL; Schäfer AJ; Floor SN; Corn JE
Nat Genet; 2018 Aug; 50(8):1132-1139. PubMed ID: 30054595
[TBL] [Abstract][Full Text] [Related]
5. Fanconi anemia gene editing by the CRISPR/Cas9 system.
Osborn MJ; Gabriel R; Webber BR; DeFeo AP; McElroy AN; Jarjour J; Starker CG; Wagner JE; Joung JK; Voytas DF; von Kalle C; Schmidt M; Blazar BR; Tolar J
Hum Gene Ther; 2015 Feb; 26(2):114-26. PubMed ID: 25545896
[TBL] [Abstract][Full Text] [Related]
6. Gene Editing With CRISPR/Cas9 RNA-Directed Nuclease.
Doetschman T; Georgieva T
Circ Res; 2017 Mar; 120(5):876-894. PubMed ID: 28254804
[TBL] [Abstract][Full Text] [Related]
7. [Advances in application of clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 system in stem cells research].
Sun SJ; Huo JH; Geng ZJ; Sun XY; Fu XB
Zhonghua Shao Shang Za Zhi; 2018 Apr; 34(4):253-256. PubMed ID: 29690746
[TBL] [Abstract][Full Text] [Related]
8. Inducibility of nuclear Rad51 foci after DNA damage distinguishes all Fanconi anemia complementation groups from D1/BRCA2.
Godthelp BC; Wiegant WW; Waisfisz Q; Medhurst AL; Arwert F; Joenje H; Zdzienicka MZ
Mutat Res; 2006 Feb; 594(1-2):39-48. PubMed ID: 16154163
[TBL] [Abstract][Full Text] [Related]
9. Enhanced genome editing in mammalian cells with a modified dual-fluorescent surrogate system.
Zhou Y; Liu Y; Hussmann D; Brøgger P; Al-Saaidi RA; Tan S; Lin L; Petersen TS; Zhou GQ; Bross P; Aagaard L; Klein T; Rønn SG; Pedersen HD; Bolund L; Nielsen AL; Sørensen CB; Luo Y
Cell Mol Life Sci; 2016 Jul; 73(13):2543-63. PubMed ID: 26755436
[TBL] [Abstract][Full Text] [Related]
10. CRISPR-Cas9 technology and its application in haematological disorders.
Zhang H; McCarty N
Br J Haematol; 2016 Oct; 175(2):208-225. PubMed ID: 27619566
[TBL] [Abstract][Full Text] [Related]
11. CRISPR-Cas9: a promising tool for gene editing on induced pluripotent stem cells.
Kim EJ; Kang KH; Ju JH
Korean J Intern Med; 2017 Jan; 32(1):42-61. PubMed ID: 28049282
[TBL] [Abstract][Full Text] [Related]
12. [CRISPR-Cas system as molecular scissors for gene therapy].
Heinz GA; Mashreghi MF
Z Rheumatol; 2017 Feb; 76(1):46-49. PubMed ID: 28124743
[TBL] [Abstract][Full Text] [Related]
13. In Vivo Delivery of CRISPR/Cas9 for Therapeutic Gene Editing: Progress and Challenges.
Mout R; Ray M; Lee YW; Scaletti F; Rotello VM
Bioconjug Chem; 2017 Apr; 28(4):880-884. PubMed ID: 28263568
[TBL] [Abstract][Full Text] [Related]
14. Induced Pluripotency and Gene Editing in Fanconi Anemia.
Navarro S; Giorgetti A; Raya A; Tolar J
Curr Gene Ther; 2017; 16(5):321-328. PubMed ID: 28103772
[TBL] [Abstract][Full Text] [Related]
15. Targeted genome engineering in human induced pluripotent stem cells from patients with hemophilia B using the CRISPR-Cas9 system.
Lyu C; Shen J; Wang R; Gu H; Zhang J; Xue F; Liu X; Liu W; Fu R; Zhang L; Li H; Zhang X; Cheng T; Yang R; Zhang L
Stem Cell Res Ther; 2018 Apr; 9(1):92. PubMed ID: 29625575
[TBL] [Abstract][Full Text] [Related]
16. Direct interaction of the Fanconi anaemia protein FANCG with BRCA2/FANCD1.
Hussain S; Witt E; Huber PA; Medhurst AL; Ashworth A; Mathew CG
Hum Mol Genet; 2003 Oct; 12(19):2503-10. PubMed ID: 12915460
[TBL] [Abstract][Full Text] [Related]
17. Cellular characterization of cells from the Fanconi anemia complementation group, FA-D1/BRCA2.
Godthelp BC; van Buul PP; Jaspers NG; Elghalbzouri-Maghrani E; van Duijn-Goedhart A; Arwert F; Joenje H; Zdzienicka MZ
Mutat Res; 2006 Oct; 601(1-2):191-201. PubMed ID: 16920162
[TBL] [Abstract][Full Text] [Related]
18. Cellular function reinstitution of offspring red blood cells cloned from the sickle cell disease patient blood post CRISPR genome editing.
Wen J; Tao W; Hao S; Zu Y
J Hematol Oncol; 2017 Jun; 10(1):119. PubMed ID: 28610635
[TBL] [Abstract][Full Text] [Related]
19. Genome editing: the road of CRISPR/Cas9 from bench to clinic.
Eid A; Mahfouz MM
Exp Mol Med; 2016 Oct; 48(10):e265. PubMed ID: 27741224
[TBL] [Abstract][Full Text] [Related]
20. The clinical phenotype of children with Fanconi anemia caused by biallelic FANCD1/BRCA2 mutations.
Myers K; Davies SM; Harris RE; Spunt SL; Smolarek T; Zimmerman S; McMasters R; Wagner L; Mueller R; Auerbach AD; Mehta PA
Pediatr Blood Cancer; 2012 Mar; 58(3):462-5. PubMed ID: 21548014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
